Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
Higher Stromal Expression of Transforming Growth Factor-beta Type II Receptors is Associated with Poorer Prognosis Breast Tumors
Authors
John Barlow
David Yandell
Donald Weaver
Theresa Casey
Karen Plaut
Publication date
01-05-2003
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2003
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1023918026437

Other articles of this Issue 2/2003

Breast Cancer Research and Treatment 2/2003 Go to the issue

OriginalPaper

EGFR, HER-2/neu, Cyclin D1, p21 and p53 in Correlation to Cell Proliferation and Steroid Hormone Receptor Status in Ductal Carcinoma in situ of the Breast

OriginalPaper

Effects of Long-Term HRT and Tamoxifen on the Expression of Progesterone Receptors A and B in Breast Tissue from Surgically Postmenopausal Cynomolgus Macaques

OriginalPaper

158. Pathological Complete Response is not the Best Prognostic Factor in Patients with Breast Cancer Treated by Preoperative Chemotherapy

OriginalPaper

Treatment of Early Stage Breast Cancer: do Surgeons and Patients Agree Regarding Whether Treatment Alternatives were Discussed?

OriginalPaper

Nutrition and Lifestyle Factors on the Risk of Developing Breast Cancer

Instructions for Authors

Breast Cancer Research and Treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits